Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease

Journal of the National Cancer Institute

Volumn 93, Issue 19, 2001, Pages 1449-1457

  Jordan, V Craig ^a   Gapstur, Susan ^a   Morrow, Monica ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CHOLESTEROL; ESTROGEN; ESTROGEN RECEPTOR; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; BONE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MOLECULAR DYNAMICS; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; TARGET ORGAN; UTERUS;

EID: 0035802285     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.19.1449     Document Type: Review

References (96)

1. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
2. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
3. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
4. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
5. Effects of hormone replacement therapy on the mammary gland of surgically post-menopausal cynomolgus macaques
6. Mammographic densities and breast cancer risk
7. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
8. Postmenopausal hormone therapy and mortality
9. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States
10. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy
11. Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study
12. Hormonal treatment of postmenopausal women
13. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
14. Estrogen replacement therapy and risk of Alzheimer disease
15. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer
16. The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole
17. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture
18. Tamoxifen in the treatment of breast cancer
19. Tamoxifen for early breast cancer: An overview of the randomised trials
20. Tamoxifen: A personal retrospective
21. The pharmacology and clinical uses of tamoxifen
22. Effects of anti-estrogens on bone in castrated and intact female rats
23. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
24. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats
25. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
26. Receptors reconsidered: A 20-year perspective
27. Cloning of a novel receptor expressed in rat prostate and ovary
28. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
29. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
30. Molecular basis of agonism and antagonism in the oestrogen receptor
31. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
32. Species-specific pharmacology of antiestrogens: Role of metabolism
33. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
34. Estrogen receptor null mice: What have we learned and where will they lead us?
35. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor
36. Nuclear receptor coactivators and corepressors
37. Peptide antagonists of the human estrogen receptor
38. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
39. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists
40. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern
41. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
42. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats
43. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
44. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
45. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
46. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
47. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
48. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
49. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
50. Validation studies for models projecting the risk of invasive and total breast cancer incidence
51. Average annual rates of invasive and noninvasive breast cancer by history of LCIS and atypical hyperplasia for participants in the BCPT
52. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors
53. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
54. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
55. The Lynn Sage Memorial Lecture: New developments in breast cancer management
56. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
57. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
58. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen
59. Coronary heart disease mortality and adjuvant tamoxifen therapy
60. Cardiovascular effects of tamoxifen in women with and without heart disease: National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators
61. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study
62. Tamoxifen therapy for breast cancer and endometrial cancer risk
63. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
64. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
65. Phase II evaluation of Ly156758 in metastatic breast cancer
66. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
67. Raloxifene hydrochloride
68. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
69. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
70. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
71. A comparison of the effects of raloxifene and estrogen on bone in post-menopausal women
72. Characterization of hot flashes reported by healthy post-menopausal women receiving raloxifene or placebo during osteoporosis prevention trials
73. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: A placebo-controlled randomized trial
74. Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects on cognitive function and mood in postmenopausal women
75. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
76. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60
77. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women
78. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium
79. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
80. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
81. Coronary and uterine vascular responses to raloxifene in the sheep
82. Raloxifene reduces atherosclerosis: Studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits
83. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys
84. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women
85. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
86. Hormone therapy to prevent disease and prolong life in postmenopausal women
87. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
88. Effect of raloxifene after tamoxifen on breast and endometrial cancer growth
89. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy
90. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening
91. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats
92. Comparative analyses of mechanistic differences among anti-estrogens
93. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen
94. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex
95. Selective estrogen receptor modulation: A personal perspective